<DOC>
	<DOCNO>NCT01999868</DOCNO>
	<brief_summary>The purpose study determine use ustekinumab , follow abatacept , prevent relapse people moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Ustekinumab Followed Abatacept Treatment Psoriasis Vulgaris</brief_title>
	<detailed_description>Psoriasis chronic immune disease skin joint affect 2 % population . The common form psoriasis plaque psoriasis , also call psoriasis vulgaris . A variety drug , include biologics , available treatment moderate severe psoriasis . When biologic agent stop , psoriasis return ( relapse ) often require biologic restart continue . No treatment program identify prevent relapse psoriasis . The study design lead-in period weight-based ustekinumab treatment , participant receive either 45 mg ustekinumab ( &lt; = 100 kg ) 90 mg ustekinumab ( &gt; 100 kg ) administer subcutaneously week 0 4 . At week 12 , participant assess Psoriasis Area Severity Index ( PASI ) 75 response ustekinumab . Participants achieve PASI 75 score discontinue investigation permit seek standard therapy .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>A diagnosis plaque psoriasis least 6 month Baseline Psoriasis Area Severity Index ( PASI ) score &gt; = 12 &gt; =10 % body surface area psoriasis involvement Willingness forgo available psoriasis therapy , live vaccine , pregnancy trial Ability willingness provide inform consent comply study requirement Nonplaque form psoriasis Grade 2 3 moderate severe psoriatic arthritis adequately manage nonsteroidal antiinflammatory drug ( NSAIDs ) Myocardial infarction , unstable angina , cerebrovascular accident , significant cardiovascular event within previous one year Chronic obstructive pulmonary disease ( COPD ) Comorbid condition require regular systemic corticosteroid treatment History malignancy , except treat basal cell skin carcinoma Treated basal cell skin carcinoma within previous 5 year Severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological disease , medical condition , investigator 's opinion , place participant risk participate study History recent ongoing uncontrolled bacterial , viral , fungal , opportunistic infection Evidence infection Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) , Human Immunodeficiency Virus ( HIV ) Positive QuantiFERONTB Gold test . Purified Protein Derivative ( PPD ) tuberculin test may substitute QuantiFERONTB Gold test . Severe reaction anaphylaxis human monoclonal antibody Any previous treatment agent target Interleukin ( IL ) 12 IL23 , include ustekinumab Any previous treatment abatacept Treatment biologic agent within previous 3 month , include adalimumab , etanercept , infliximab Treatment immunosuppressive medication , include methotrexate , cyclosporine , oral retinoids , prednisone , phototherapy within previous 4 week Topical psoriasis treatment within previous 2 week , include topical corticosteroid , vitamin D analogue , retinoids , calcineurin inhibitor , salicylic acid , coal tar Investigational study medication within previous 6 month Liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase ) result &gt; /= 2x upper limit normal ( ULN ) . Serum creatinine &gt; = 2x ULN . Any follow hematologic abnormality , confirm repeat test least 1 week apart : 1 . White blood count &lt; 3,000/μL &gt; 14,000/μL ; 2 . Lymphocyte count &lt; 1,000/μL ; 3 . Neutrophil count &lt; 1,500/μL ; 4 . Platelet count &lt; 150,000 /μL ; 5 . Hemoglobin &lt; 10 g/dL . Females pregnant , lactating , plan pregnancy study period , unwilling use FDAapproved method birth control Receipt live vaccine ( e.g. , varicella , measles , mumps , rubella , coldattenuated intranasal influenza vaccine , smallpox ) 6 week enrollment BCG ( Bacillus CalmetteGuérin ) vaccine one year prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>psoriasis vulgaris</keyword>
	<keyword>ustekinumab</keyword>
	<keyword>abatacept</keyword>
</DOC>